Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.37 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377586 | 0.88 | ALDH1A1 (0.48) | BDKRB1HTTCDK8CLK4SMN1; SMN2 | |
| SCHEMBL5385755 | 0.86 | BDKRB1 (0.45) | BDKRB1PTGDR2LTB4RLTB4R2CDK8 | |
| SCHEMBL5390477 | 0.85 | BDKRB1 (0.38) | BDKRB1LTB4RLTB4R2CDK8CLK4 | |
| SCHEMBL5396899 | 0.84 | BDKRB1 (0.44) | BDKRB1PTGDR2CDK8CLK4TSHR | |
| SCHEMBL5393673 | 0.82 | BDKRB1 (0.43) | BDKRB1PTGDR2LTB4RLTB4R2TSHR | |
| SCHEMBL5402470 | 0.82 | BDKRB1 (0.43) | BDKRB1PTGDR2CDK8CLK4TSHR | |
| SCHEMBL5385870 | 0.81 | RAB9A (0.46) | HTTLTB4RLTB4R2CDK8CLK4 | |
| SCHEMBL5402491 | 0.81 | ALDH1A1 (0.49) | HTTTSHR | |
| SCHEMBL5385080 | 0.80 | BDKRB1 (0.65) | BDKRB1 | |
| SCHEMBL5388679 | 0.79 | FNTA (0.39) | BDKRB1LTB4RLTB4R2TAS2R14TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | BDKRB1 1/4885HTT 3739/4885PTGDR2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.